Additional file 3: of A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial

List of all ethical bodies that approved the EPAZ study. (DOCX 14 kb

Additional file 1: of Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples - a multicentre phase 3 diagnostic accuracy study

Quality Assurance/Monitoring. (DOC 31 kb

Port025-2017-0814-BancaPDM

aGerman unit costs according to Bock et al. [19]. bIndirect costs only for subjects of employable age < 65 years. cWork absence only for full-time and regular part-time employees. (DOC 40 kb

Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation

<p><b>Background:</b> The efficacy and safety of renin angiotensin aldosterone system blockers (RAASB’s) if introduced immediately after renal transplantation have not been extensively investigated.</p> <p><b>Methods:</b> The medical charts of 142 kidney transplant recipients who received a RAASB in the early postoperative period and of 114 matched controls were analyzed. The RAASB was given primarily for blood pressure control.</p> <p><b>Results:</b> 117 patients continued to receive and 50 controls remained continuously free of the RAASB in the first year. The RAASB was added on average at postoperative day 8 and the mean duration of follow-up was 5.4 years. Systolic, blood pressure at treatment initiation was increased in the RAASB group (150 ± 17 vs. 141 ± 16, <i>p</i> < 0.001). At discharge from hospital and during follow-up blood pressure was similar in both groups, without differences in GFR, potassium and proteinuria. The endpoints “graft failure” and “graft failure or death from any cause” were significantly better in patients treated with RAASB’s (<i>p</i> = 0.03 and <i>p</i> = 0.04, respectively). The treatment effects in the RAASB group persisted even after adjustment for demographic parameters, immunological risk factors, peritransplant risk factors, duration of dialysis prior to transplantation and medical comorbidities.</p> <p><b>Conclusions:</b> Thus, RAASB’s can be used effectively and safely to treat hypertension in the early postoperative period after kidney transplantation and are renoprotective in the long term.</p

Additional file 1: Table S1. of Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities

Correlations between HRQL instruments and with GOLD grade and BODE as clinical measures: Spearman Correlation Coefficients. Table S2. Adjusted mean EQ-5D utilities, EQ-5D VAS, CAT score, SGRQ total scores for COPD grade 1–4 stratified for group with low (≤3) or high (>3) number of comorbidities. Table S3. Results of regression models considering interactions between COPD grades and low/high number of comorbidity. Figure S1. Lifetime prevalence of self-reported comorbidities (%) in the study population. Figure S2. HRQL scores by FEV1 % pred.: non-parametric quantile regression: quantile fit plots for FEV1 % pred. (DOC 258 kb

Additional file 2: of Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Indirect costs only include participants < 65 years of age. Significant estimates on a level of p < .05 are printed bold. A = COPD patients without AATD, B1 = COPD patients with Alpha-1-antitrypsin deficiency (AATD) and augmentation therapy (AT), B2 = COPD patients with AATD but without AT. Other costs include physiotherapist and rehabilitation costs. (DOC 68 kb

Additional file 1: Table S1. of Cardiovascular risk in patients with alpha-1-antitrypsin deficiency

Analysis of lung density by CT (available for 379 patients). (f) n = 3 missings, (g) n = 89 missings, *panlobular emphysema, PLE; centrilobular emphysema, CLE. Table E2. Multivariate linear regression model with TLCO %pred. as dependent variable. AATD refers to the presence of AATD versus COPD. Figure S1. Patients with AATD revealed a reduced TLCO %pred at similar levels of ITGV %pred. (A, B) or BMI (B, D) for both female and male patients after adjustment for FEV1, sex, BMI, packyears, and age (AATD - dotted line, COPD - straight line). Table S3. Results (Odds Ratio [95% confidence interval] and p-value) of multivariable logistic regression analyses for different comorbidities as dependent variable. (DOCX 265 kb